Table 4.
High/not high model
| Gene | Name | P-Value |
|---|---|---|
| VKORC1 | Vitamin K1 2,3-epoxide reductase subunit 1 | 4.39E-06 |
| CYP2C9 | cytochrome P450, family 2, subfamily C | 2.27E-04 |
| QTRTD1 | queuine tRNA-ribosyltransferase domain | 3.21E-04 |
| NAT13 | N-acetyltransferase 13 | 5.25E-03 |
| BAT5 | HLA-B associated transcript 5 | 6.76E-03 |
| CRP | C-reactive protein, pentraxin-related | 1.02E-02 |
| COL1A2 | Alpha-2 type I collagen | 1.37E-02 |
| GGCX | Vitamin K gamma glutamyl carboxylase | 1.44E-02 |
| A2M | C3 and PZP-like alpha-2-macroglobulin | 2.06E-02 |
| FBXO28 | F-box protein 28 | 2.14E-02 |
| HSD3B7 | 3-beta-HSD VII | 2.54E-02 |
| ITGA5 | Fibronectin receptor subunit alpha | 4.07E-02 |
| ALS2 | amyotrophic lateral sclerosis 2 | 4.13E-02 |
| NSUN6 | NOL1/NOP2/Sun domain family 6 | 4.21E-02 |
| SORBS3 | sorbin and SH3 domain containing 3 | 4.99E-02 |
Top 15 genes with candidate gene-scores that significantly distinguish between high dose patients and non-high-dose patients (p≤0.05). P-Values are result of t test between low-dose and non-low-dose distributions of gene-scores. Genes in bold are significant after correcting for multiple hypothesis testing.